Handheld Fluorescence Imaging for Surgical Margin Assessment

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current surgical methods for tumor removal, particularly breast conservation surgery, face challenges in accurately visualizing tumor margins due to low tumor-to-normal tissue contrast under white light, leading to high rates of reoperation and increased healthcare costs, as existing technologies struggle to spatially co-localize positive margins on excised tissue to the surgical bed.

Innovation Solution

A handheld, white light and fluorescence-based imaging device that uses excitation light to induce porphyrin fluorescence in cancerous tissue, allowing real-time visualization of surgical margins and guiding the removal of residual cancer cells, precancerous cells, and satellite lesions, combined with a multispectral system for enhanced imaging capabilities.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Illumination intensity

If standard white light imaging is used during surgery, then the surgical procedure is simple and quick, but the tumor-to-normal tissue contrast is low making margin visualization challenging

Engineering Contradiction:
Improvetumor-to-normal tissue contrastVSAvoidimaging device complexity
Core Design Contradiction:
Illumination intensityVSDevice complexity

Solution Approach 1:

The patent applies fluorescence imaging that causes cancerous tissue to emit light at different wavelengths than normal tissue. The excitation light source illuminates the surgical site, and cancerous tissue fluoresces with a distinct color signature, enabling real-time visualization of tumor margins with high contrast against normal tissue during the surgical procedure.

Inventive Principle:
Principle #32Color changes

Solution Approach 2:

The patent uses fluorescence imaging as an intermediary technique between standard white light imaging and pathological analysis. The fluorescence modality acts as a mediator that provides real-time margin assessment during surgery, bridging the gap between intraoperative visualization needs and accurate tumor identification without requiring complex additional equipment.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Measurement precision

If visual inspection under white light is used to assess surgical margins, then the process is fast, but the accuracy of detecting residual cancer cells is low leading to high reoperation rates

Engineering Contradiction:
Improvesurgical margin assessment accuracyVSAvoidsurgical time
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

The fluorescence imaging system enables continuous real-time assessment of surgical margins during the entire resection process. The excitation light source continuously illuminates the tissue, and the imaging device continuously captures fluorescence signals, allowing the surgeon to assess margins continuously rather than relying on intermittent white light inspection, thereby improving detection accuracy without significant time loss.

Inventive Principle:
Principle #20Continuity of useful action

Solution Approach 2:

The system provides immediate visual feedback to the surgeon about the presence of residual cancer cells at the surgical margins. The fluorescence signal gives real-time information about tumor boundaries, allowing the surgeon to adjust the resection in real-time to achieve complete margin clearance, thereby improving measurement precision while maintaining surgical efficiency.

Inventive Principle:
Principle #23Feedback

3Reliability

If conservative resection is performed to preserve healthy tissue, then cosmetic outcomes are improved, but the risk of leaving residual cancer cells increases

Engineering Contradiction:
Improvecomplete tumor removal reliabilityVSAvoidhealthy tissue removal
Core Design Contradiction:
ReliabilityVSLoss of substance

Solution Approach 1:

The fluorescence imaging system enables local differentiation between cancerous and normal tissue at the surgical margins. By visualizing the precise location and extent of residual cancer cells through their unique fluorescence signature, the surgeon can selectively remove only the affected areas while preserving adjacent healthy tissue, thereby improving complete tumor removal reliability without excessive loss of healthy substance.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables real-time, accurate visualization and targeted removal of residual cancer cells, reducing reoperation rates and improving surgical outcomes by providing precise guidance for tumor margin assessment and treatment.

Implementation Method 1

at least one excitation light source configured to excite autofluorescence emissions of tissue cells and fluorescence emissions of induced porphyrins in tissue cells of the surgical margin

Methodology Applied
Scientific EffectFluorescence: Fluorescence

Data Source

PatentEP3745951B1Devices, systems, and methods for tumor visualization and removal
Publication Date: 2026.03.25 UNIV HEALTH NETWORK
  • EP3745951B1 patent drawingFigure 1A
  • EP3745951B1 patent drawingFigure 1B
  • EP3745951B1 patent drawingFigure 2A

AI summary

A method of assessing surgical margins is disclosed. The method includes, subsequent to administration of a compound configured to induce emissions of between about 600 nm and about 660 nm in cancerous tissue cells, positioning a distal end of a handheld, white light and fluorescence-based imaging device adjacent to a surgical margin. The method also includes, with the handheld device, substantially simultaneously exciting and detecting autofluorescence emissions of tissue cells and fluorescence emissions of the induced wavelength in tissue cells of the surgical margin. And, based on a presence or an amount of fluorescence emissions of the induced wavelength detected in the tissue cells of the surgical margin, determining whether the surgical margin is substantially free of at least one of precancerous cells, cancerous cells, and satellite lesions. The compound may be a non-activated, non-targeted compound such as ALA.